Calcitonin, also called thyrocalcitonin, is a linear polypeptide hormone produced in human thyroid glands by parafollicular cells. In fish, birds, and other non-mammalian animals, calcitonin is produced by cells of ultimobranchial body. Calcitonin lowers the levels of calcium and phosphate in blood and promotes the bone formation. Calcitonin inhibits the bone removal cells called osteoclasts and simultaneously promotes bone formation cells called osteoblasts. The potency of calcitonin salmon per mg is greater and has longer duration of action than calcitonin produced by mammalian origin. Calcitonin salmon is produced either by synthetic processes or by microbial processes using recombinant DNA technology. Calcitonin salmon is available in two forms: injection and nasal. Miacalcin and Fortical are commonly available brands for calcitonin salmon. Calcitonin salmon is used for indications such as osteoporosis, hypercalcemia, Paget’s disease of bone, and other bone related diseases.

Get Sample Report at: http://bit.ly/2lWJQJY

The global calcitonin salmon market is driven by increasing number of osteoporosis patients globally. According to the International Osteoporosis Foundation, over 8.9 million people suffer from osteoporosis globally each year. Osteoporosis is more dominant in women than men and is common in geriatric population. The International Osteoporosis Foundation study reveals that over 200 million women are affected by osteoporosis globally. The FDA advisory committee has recommended to prevent use of calcitonin salmon for the treatment of postmenstrual osteoporosis in women as there exists a potential risk of cancer development. Moreover, calcitonin salmon is used as second line of treatment for osteoporosis. Side effects of calcitonin salmon are likely to be key restraints of the global market. Large number of people are not aware about having osteoporosis until they have first fracture and also Paget’s disease is not common in people. These factors hamper the growth of the calcitonin salmon market. Easy availability of other medications for the first line treatment of osteoporosis and related diseases is likely to restrain the market. The FDA advisory committee has suggested to companies developing new calcitonin salmon products to prove its effectiveness in reducing bone fractures. This is expected to boost the market.

The global calcitonin salmon market has been segmented based on route of administration and type of indication. Calcitonin salmon can be administered through injection or by nasal spray. The calcitonin nasal spray is indicated for patients for whom alternative treatments are not suitable. Calcitonin injections are used for the treatment of Paget’s disease of bone and hypercalcemia. It can be administered through subcutaneous, intramuscular, and intranasal routes. Calcitonin salmon is used for the treatment of osteoporosis, Paget's disease, and hypercalcemia.

Geographically, the global calcitonin salmon market has been segmented into five regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Over 75 million people are estimated to be affected by osteoporosis in the U.S., Europe, and Japan. This highlights the growth opportunity in these regions. Prevalence of osteoporosis is higher in Middle East & Africa than in countries in the West. This is expected to propel the calcitonin salmon market in this region. Increasing geriatric population with bone related diseases is likely to fuel the growth of the market in Asia Pacific during the forecast period.

Browse Complete Report with TOC at: http://www.transparencymarketresearch.com/calcitonin-salmon-market.html

Key players in the calcitonin salmon market include Novartis AG, Apotex, Inc., Upsher-Smith Laboratories, Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., and United Biotech (P) Limited. Novartis AG, Upsher-Smith Laboratorie, Inc., and Torrent Pharmaceuticals are the leading players in the global calcitonin salmon market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com